LYEL Lyell Immunopharma
- 2.440
- +0.080+3.39%
Lyell Immunopharma News
Lyell Immunopharma | 424B5: Prospectus
Lyell Immunopharma | 10-Q: Quarterly report
Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Lyell Immunopharma | EFFECT: Others
Lyell Immunopharma | ARS: Annual Report to Security Holders
Lyell Immunopharma | DEFA14A: Others
Lyell Immunopharma | DEF 14A: Definitive information statements
Lyell Immunopharma | S-3: Registration statement for specified transactions by certain issuers
Lyell Immunopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Lyell Immunopharma | 10-K: Annual report
Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund IX, L.P.(14.5%),ARCH Venture Fund IX Overage, L.P.(14.5%), etc.
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lang Matthew
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Hill Stephen J.
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lee Gary K.
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Newton Charles W.
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Seely Lynn
Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)
Lyell Immunopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.7%)
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Newton Charles W.
Analysis
Price Target
No Data
